Compare VTR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTR | ONC |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1B | 33.5B |
| IPO Year | 2005 | N/A |
| Metric | VTR | ONC |
|---|---|---|
| Price | $85.78 | $299.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $84.77 | ★ $386.70 |
| AVG Volume (30 Days) | ★ 2.5M | 224.8K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 184.21 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $5,833,980,000.00 | N/A |
| Revenue This Year | $12.42 | $759.19 |
| Revenue Next Year | $8.32 | $14.51 |
| P/E Ratio | ★ $159.15 | $614.06 |
| Revenue Growth | ★ 18.47 | N/A |
| 52 Week Low | $60.15 | $196.53 |
| 52 Week High | $87.87 | $385.22 |
| Indicator | VTR | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 59.37 | 34.99 |
| Support Level | $66.18 | $292.79 |
| Resistance Level | $87.56 | $300.00 |
| Average True Range (ATR) | 1.35 | 9.26 |
| MACD | -0.36 | -4.29 |
| Stochastic Oscillator | 44.83 | 12.16 |
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.